IMMUNOTHERAPY

A retrospective study of tumor-infiltrating lymphocyte therapy showed that despite its benefit, many patients were unable to receive lifileucel.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

The LARA trial reveals promising results for pembrolizumab and lenvatinib in treating recurrent clear cell gynecological cancer, showcasing effective antitumor activity.

Neoadjuvant pembrolizumab showed promising high response rates and melanoma-specific survival outcomes in desmoplastic melanoma.

A large-scale analysis reveals novel predictors of survival and resistance mechanisms in metastatic breast cancer treated with T-DXd, enhancing patient stratification.

The COLIBRI study reveals that neoadjuvant dual immune checkpoint blockade enhances treatment outcomes for locally advanced cervical cancer, showing promising immune responses.

A recent study reveals CAR T-cell therapy patients in Europe experience quality of life comparable to the general population, yet face ongoing physical and mental challenges.

A phase 2 trial reveals elraglusib shows potential benefits in select patients with recurrent salivary gland carcinomas despite missing primary response goals.

Ultrasensitive ctDNA analysis reveals early predictive insights for immunotherapy outcomes in advanced solid tumors, enhancing patient management and survival predictions.

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising new hope for cancer treatment.

FDA fast-tracks muzastotug and pembrolizumab for metastatic colorectal cancer, showcasing promising efficacy and safety in early studies.

Inaregacestat shows promising results in treating desmoid tumors, significantly improving progression-free survival and reducing tumor volume in recent trials.

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.

New trial data reveals IGV-001 enhances overall survival in glioblastoma patients, marking a potential breakthrough in treatment options.

Naxitamab combined with GM-CSF shows promising results in treating high-risk neuroblastoma, achieving high response rates and manageable safety profiles.

Givastomig shows promising antitumor activity and a manageable safety profile in patients with CLDN18.2-positive gastroesophageal carcinoma.

Axi-cel shows impressive long-term efficacy in treating relapsed/refractory indolent non-Hodgkin lymphoma, with potential curative outcomes for patients.

Recent research reveals that GLP-1 receptor agonists significantly lower 5-year mortality rates in colon cancer patients, highlighting their potential in cancer treatment.

The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.

A novel combination therapy shows promising results in extending progression-free survival for patients with advanced pancreatic cancer, highlighting potential biomarkers for immunotherapy.

OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.

DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

The FDA grants fast track designation to 4A10, a promising monoclonal antibody for treating relapsed acute lymphoblastic leukemia in children.